Kabamba Kabeya

1.7k total citations
23 papers, 638 citations indexed

About

Kabamba Kabeya is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Kabamba Kabeya has authored 23 papers receiving a total of 638 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 15 papers in Virology and 5 papers in Epidemiology. Recurrent topics in Kabamba Kabeya's work include HIV/AIDS drug development and treatment (16 papers), HIV Research and Treatment (15 papers) and HIV/AIDS Research and Interventions (10 papers). Kabamba Kabeya is often cited by papers focused on HIV/AIDS drug development and treatment (16 papers), HIV Research and Treatment (15 papers) and HIV/AIDS Research and Interventions (10 papers). Kabamba Kabeya collaborates with scholars based in Belgium, United Kingdom and United States. Kabamba Kabeya's co-authors include Nathan Clumeck, Sophie Bouchat, Carine Van Lint, Olivier Rohr, Tab Bonny, Lloyd Curtis, Kimberly K. Adkison, H. M. Steel, W. Garrett Nichols and Judith Millard and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Scientific Reports.

In The Last Decade

Kabamba Kabeya

23 papers receiving 628 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Kabamba Kabeya 438 397 135 101 95 23 638
Mary O’Hearn 676 1.5× 599 1.5× 136 1.0× 106 1.0× 39 0.4× 9 838
Nhut Le 289 0.7× 351 0.9× 110 0.8× 107 1.1× 26 0.3× 24 588
Ann Thorkelson 371 0.8× 525 1.3× 99 0.7× 50 0.5× 27 0.3× 6 617
PM Girard 238 0.5× 192 0.5× 145 1.1× 66 0.7× 24 0.3× 37 525
Meghan Rothenberger 350 0.8× 455 1.1× 100 0.7× 56 0.6× 29 0.3× 14 644
Anna Orani 262 0.6× 204 0.5× 157 1.2× 34 0.3× 35 0.4× 25 486
Marina Korneyeva 566 1.3× 525 1.3× 56 0.4× 99 1.0× 22 0.2× 7 702
Catherine Fagard 865 2.0× 847 2.1× 184 1.4× 59 0.6× 14 0.1× 33 1.0k
Nancy Ruíz 965 2.2× 859 2.2× 166 1.2× 88 0.9× 24 0.3× 21 1.1k
Julie Lewis 375 0.9× 737 1.9× 222 1.6× 95 0.9× 48 0.5× 6 958

Countries citing papers authored by Kabamba Kabeya

Since Specialization
Citations

This map shows the geographic impact of Kabamba Kabeya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kabamba Kabeya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kabamba Kabeya more than expected).

Fields of papers citing papers by Kabamba Kabeya

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kabamba Kabeya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kabamba Kabeya. The network helps show where Kabamba Kabeya may publish in the future.

Co-authorship network of co-authors of Kabamba Kabeya

This figure shows the co-authorship network connecting the top 25 collaborators of Kabamba Kabeya. A scholar is included among the top collaborators of Kabamba Kabeya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kabamba Kabeya. Kabamba Kabeya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kumar, Amit, Wasim Abbas, Sophie Bouchat, et al.. (2016). Limited HIV-1 Reactivation in Resting CD4+ T cells from Aviremic Patients under Protease Inhibitors. Scientific Reports. 6(1). 38313–38313. 10 indexed citations
2.
Best, Brookie M., Stein Schalkwijk, Jiajia Wang, et al.. (2015). Maraviroc Pharmacokinetics in HIV-1–Infected Pregnant Women. Clinical Infectious Diseases. 61(10). 1582–1589. 13 indexed citations
3.
Spiegelaere, Ward De, Jan Philippé, Chris Verhofstede, et al.. (2015). Comparison of Methods for In-House Screening of HLA-B*57:01 to Prevent Abacavir Hypersensitivity in HIV-1 Care. PLoS ONE. 10(4). e0123525–e0123525. 10 indexed citations
4.
Berghe, Wim Vanden, Stéphane De Wit, Kabamba Kabeya, et al.. (2015). Risk Factors for HCV Acquisition Among HIV-Positive MSM in Belgium. JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5). 585–593. 49 indexed citations
5.
Colbers, Angela, Carmen Hidalgo-Tenorio, Kabamba Kabeya, et al.. (2015). Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy. Clinical Infectious Diseases. 61(5). 809–816. 48 indexed citations
6.
Bouchat, Sophie, Nadège Delacourt, Anna Kula, et al.. (2015). Sequential treatment with 5‐aza‐2′‐deoxycytidine and deacetylase inhibitors reactivates HIV ‐1. EMBO Molecular Medicine. 8(2). 117–138. 70 indexed citations
7.
Clumeck, Nathan, et al.. (2014). First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting. AIDS. 28(8). 1143–1153. 13 indexed citations
8.
Clumeck, Nathan, Kabamba Kabeya, Vincent Cálvez, et al.. (2014). First-line therapy with LPV/r vs NVP and 2 NRTIs in a developing country: W144 of a randomized trial. BMC Infectious Diseases. 14(S2). 7 indexed citations
9.
Colbers, Angela, David Hawkins, Andrea Gingelmaier, et al.. (2012). The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS. 27(5). 739–748. 60 indexed citations
10.
Bouchat, Sophie, Kabamba Kabeya, Laurence Colin, et al.. (2012). Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patients. AIDS. 26(12). 1473–1482. 122 indexed citations
11.
Clumeck, Nathan, Kabamba Kabeya, Dolorès Vaira, et al.. (2011). The Lubumbashi Trial: Week 48 Data: Comparison between Lopinavir/r (LPV/r) versus Nevirapine (NVP)-based Regimens in Treatment-naïve Patients in a Developing Country. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 4 indexed citations
12.
Vandenbroucke, Ina, Herwig Van Marck, Wendy Mostmans, et al.. (2010). HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays. AIDS Research and Therapy. 7(1). 4–4. 32 indexed citations
13.
Covens, Kris, Kabamba Kabeya, Jan Balzarini, et al.. (2010). The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide. Antiviral Research. 86(3). 253–260. 6 indexed citations
14.
Vandekerckhove, Linos, Chris Verhofstede, Els Demecheleer, et al.. (2010). Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. Journal of Antimicrobial Chemotherapy. 66(2). 265–272. 21 indexed citations
15.
Covens, Kris, Kabamba Kabeya, Yoeri Schrooten, et al.. (2009). Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes. Journal of Clinical Virology. 44(4). 325–328. 7 indexed citations
16.
Verhofstede, Chris, Eva Poveda, Eduardo Seclén, et al.. (2009). Correlation between population based-sequencing and viral tropism determination on PBMC DNA and plasma RNA in comparison with phenotypic methods. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 1 indexed citations
17.
Nichols, W. Garrett, H. M. Steel, Tab Bonny, et al.. (2007). Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140). Antimicrobial Agents and Chemotherapy. 52(3). 858–865. 117 indexed citations
18.
Wit, Stéphane De, S Sprecher, Yves Van Laethem, et al.. (1998). Salvage anti HIV triple therapy with Foscarnet in combination with Nelfinavir and Nevirapine in heavily pretreated patients. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 1 indexed citations
19.
Clumeck, Nathan, Kabamba Kabeya, Déborah Konopnicki, et al.. (1998). MIRO: a randomized trial of maintenance therapy with or whitout protease inhibitors after 4 months of triple or quadruple induction therapy. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 5 indexed citations
20.
Cassano, Patricia A., et al.. (1998). Combined quadruple therapy with Ritonavir-Saquinavir+ nucleosides in patients who failed in triple therapy with Ritonavir, Saquinavir or Indinavir. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary O’Hearn Breakdown of academic impact, for papers by Nhut Le Breakdown of academic impact, for papers by Ann Thorkelson Breakdown of academic impact, for papers by PM Girard Breakdown of academic impact, for papers by Meghan Rothenberger Breakdown of academic impact, for papers by Anna Orani Breakdown of academic impact, for papers by Marina Korneyeva Breakdown of academic impact, for papers by Catherine Fagard Breakdown of academic impact, for papers by Nancy Ruíz Breakdown of academic impact, for papers by Julie Lewis
Rankless by CCL
2026